

Europäisches Pat ntamt
European Patent Offic
Office eur péen d's brev ta



(ii) EP 1 103 623 A1

(12)

EUROPEAN PATENT APPLICATION

- (43) Date of publication: 30.05,2001 Bulletin 2001/22
- (21) Application number: 00127074,3
- (22) Date of filing: 07.01.1988
- g: 07.01.1988
- (84) Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE
- (30) Priority: 07.01.1987 GB 8700279 07.01.1987 GB 8700269 22.04.1987 US 41306 09.11.1987 GB 8726172
- (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: 97113748.4 / 0 823 438 88900775.3 / 0 341 252
- (71) Applicant: IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED London WC2A 3NL (GB)

- (51) Int CLY: C12Q 1/68, A61K 31/70, C07K 16/18, C07K 14/47, C07K 7/00, C12N 5/20, A61K 38/16, A61K 39/395, G01N 33/574
- (72) Inventors:
 - Taylor-Papadimitriou, Joyce Lincoln's Inn Fields, London, WC2 (GB)
 Burchell, Joy
 - Lincoln's Inn Fields, London, WC2 (GB) Gendler, Sandra
 - Scottsdale, Arizona 85255 (US)
- (74) Representative: Cresswell, Thomas Anthony J.A. KEMP & CO. 14 South Square Gray's Inn London WC1R 5LX (GB)

Remarks:

This application was filed on 11 - 12 - 2000 as a divisional application to the application mentioned under INID code 62.

- (54) Human mucin core protein: nucleic acid probes, peptide fragments and antibodies thereto, and uses thereof in diagnostic and therapeutic methods
- (57) An antibody or fragment thereof against a human mucin core protein which antibody or fragment has

reduced or substantially no reaction with fully expressed human mucin glycoprotein.

D scription

[0001] The present invention relates to DNA probes for detecting a tandemly-repeated nucleotide sequence in the gene encoding mucin lydporpotein expressed by human mammary epithelial cells, to the use of the probe in diagnosis and in "fingerprinting" individuals, to the polypeptides expressed by the corresponding mucin gene, to ambodies against the polypeptides and to the use of the polypeptides and antibodies in the diagnosis and therapeutic treatment of cancer.

[0002] Normal and malignant human mammary epithelial cells express high molecular weight glycoproteins (gps) which are extensively glycoproteins and and very antigenic. As a result, many of the monoclonal anabodies (Mkbs) selected for reactivity with human breast cancer and other cardinomas are found to react with noticules which are produced in abundance by the fully differentiated human mammary tissue and are found in the milk fat globule (MFQ) and in milk. However, the level of expression of a particular antigenic determinant may be different in the gps produced by the normal differentiated cell and in the similar molecules produced by breast cancers. This means that some antibodies can show a coratin speciality for reacting with umoru gps.

5 0003] The molecules bearing the pilipose recognised by these artibodies are complex and have been difficult to analyse, both because they are large and heavily glycocylated (e/250,000 datons) and because of the complex patient of expression. Two of the MAbs, HMFG-1 and -2, react with a component in human milk which appear as the greater than 400,000 datons, whereas the molecules bound in sear and tumous are smaller, although the dominant components are still greater than 200,000 dathors, on immunoblots. The large glycoprotein produced by the differentiated mammary epithelial calls found in human milk or in the milk lat globule has been purified and shown to have some of the characteristies of the mucilies. This component contains a large amount of carbodytestal piloriat foll-induced to serine and threorine residues via the finkage sugar Nacetylgalacteramine. Moreover, the core protein contains high levels of serine, thronoine and profine and toll welvels of a formatic and subject containing acids.

[0004] These mucin-like glycoprotoins are also secreted by a number of other normal epithelial cells. The monoclonal artibody HMFG-1 is highly reactive with the milk mucin and evidence suggests that the epitope recognised by this artibody is more abundant on the fully processed mucin, characteristic of normal differentiation.

[0005] In tumours, the molecular weight of the molecules carrying these artigenic determinants differs among individual tumours and, in the case of the components recognised by the HMF-G2 anthody, can range from 69-400K dations. Although it appears that the differences observed in the mobility of the high molecular weight bunck are due to genetic polymorphism this probably does not explain variations in the size of the lover bunds. It has been proposed that these may be the result of aberrant processing occurring in the tumour cell possibly within the glycosylation pathways.

[0005] For the majority of the monoclonal artibodies reacting with this group of molecules the exact nature of the antigenic epitops remains unclear but circumstartial evidence has suggested that carbohydrate may at least be partly involved in many of the epitops. Moreover, from perviously available data it was not known whether the muoin found in the normal differentiated cells, and that observed in the tumours, contain the same core protein, or just carry common carbohydrate determinants.

[8007] Mucin has now been isolated from human milk by affinity chromatography enabling identification of the core protein and the gene encoding the protein. This has been found to be a highly polymorphic gene defined by the peanut urinary mucin (PUM) locus [see Swallow et al., [Jessee Markers, 4, 247, (1986) and Martue, 227, 824 (1987)]. The gene product, which is hereafter reterred to as human polymorphic opithelial mucin or HPEM, has been detected in breast tumours and other carcinomas as well as in some normal polythelial issues.

[0008] It has now been found that the HPEM core protein has epitopes which also appear in the aberrantly processed gps produced by adenocarcinoma cells. Certain of these epitopes are not exposed in the fully processed mucin glycoprotein produced by the lactation mammay cland.

[0009] In one aspect the present invention therefore provides an antibody against a human mucin core protein which antibody substantially does not react with a fully processed human mucin glycoprotein.

[0010] As used herein the term "antibody" is intended to include fragments of antibodies bearing antigen binding sites such as the F(ab), fragments.

[0011] Antibodies according to the present invention react with HPEM core protein, especially as expressed by colon, lung, ovary and particularly breast carcinomas, but have reduced or no reaction with the corresponding fully processed HPEM. In a particular aspect the antibodies eact with HPEM core protein but not with fully processed HPEM glycoprotein as produced by the normal leatating human mammary gland.

[0012] Antibodies according to the present invertion have no significant reaction with the mucin glycoproteins prosourced by pregnant or lactating mammary epithelial tissues but react with the mucin proteins expressed by mammary epithelial adocoarcinoma cells. Those antibodies show a much reduced reaction with benign breast tumours and are therefore useful in the diagnosis and localisation of breast cancer as well as in therapeutic methods.

[0013] The antibodies may be used for other purposes including screening cell cultures for the polypeptide expression

product of the human mammary epithelial mucin gene, or fragments thereof, particularly the nascent expression product. In this case the antibodies may conveniently be polyclonal or monoclonal antibodies.

[0014] Antibodies according to the present invention may be produced by innoculation of suitable animals with HEEM oran protein or a fragment thereof such as the specifieds descrabed below. Monoclored artibodies are produced by the method of Kohler & Milesien (Nature 256, 468-4971975) by immortalising spleen cells from an animal innoculated with the mucin core protein or a fragment thereof, usually by fusion with an immortal cell line (preferably a myelom a cell line), of the same or a different species as the innoculated animal, followed by the appropriate cloning and cerening states.

[0015] In a particular aspect the present invention provides the monocional artibodies designated SM3 against the HPEM core protein. In another a spect the invention provides the hydroidino and sill now which secretes the artibodies SM3 and has been designated HSM3. Samples of HSM3 have been deposited with ECACC on 7th January 1987 under accession unmber 87010701.

[0016] Using ambodies according to the invention it has been possible to acreen a phage Brany constructed from mPNA isolated from a human broat cancercellifies to identify sequences coding to protings of the must comp protein. Complementary DNA sequences have been constructed and from those it has surprisingly been found that the gene encoding the core protein contains multiple tander repeats of a 60 base sequence seding to considerable polymorphism sufficiently extensive that cDNA fragments corresponding to the repeat sequence would be useful for fingsprinting DNA. The fingsprinting thus made possible has applications in for instance accordanting whether bone marrow growth after transplants is from the host or the donor and in forensic modicine for identifying individuals using body issues or fullic.

[0017] Accordingly the present invention also provides a nucleic acid fragment comprising at least 17 nucleotide bases the fragment being hybridisable with at least one of

a) the DNA sequence

30

25

45

55

b) DNA complementary to the DNA of a), i.e. of sequence

5"
GTC ACC TGG GCC CGG GAC ACC AGG CCG GCCCGG GGC TCC ACC GCC CCA GCC CAC GGTGTC ACC TCG GCC CCG GAC ACC AGG CCG
GCC GCG GCC TCC ACC GCC CCA GCC CAC GGT-

c) RNA having a sequence corresponding to the DNA sequence of a) and

d) RNA having a sequence corresponding to the complementary DNA sequence of b).

[0018] The sequences in (a) and (b) each include a double tandom repeat sequence of 120 bases. Fragments according to the invention may correspond to any portion of this sequence including portions bridging the start point of the repeat,

[0019] Fragments according to the invertion will hybridise under conditions of low stringency with the DNA and RNA sequences (a) for (d) above. Preferred fragments are those which also hybridise under conditions of high stringency. The most preferred fragments or the invention are those which have sequences exactly identical to, or exactly complementary to the sequences (a) of above.

[0020] Normally a given DNA or RNA fragment according to the invention will be capable of hybridising with both DNA according to a) and RNA according to c) or with both DNA according to b) and RNA according to d) above.

[0021] Preferably the nucleic acid fragment according to the present invention will comprise a portion of at least 30 mucleoticle bases capable of hybridising with at least one of a) to a) down, once preferably at least 50 exits bases and most preferably the fragment contains a sequence of 60 bases exactly complementary to one of the repeat sequence of a), b) c) or d) above. Cher fragments of the invention may comprise two or more repeats of such a sequence, potentially with minor variations by way of substitution. Preferably such fragments include an integral number of such

repeal sequences. Further fragments of the invention comprise the landom repeat sequence and additional coding or non-coding 6 and/or 3 flanking sequences corresponding to the HPEM gene or a portion thereof. [0022] When the existence of a tandem repeat sequence was first identified it was believed that the sequence con-

5 sisted of 99 base pairs corresponding with the sequence indicated in (a) and (b) above except for the lack of the base indicated with ***.
[0023] Many fragments according to the invention as originally defined in British Patent Application No. 870259

[0023] Many fragments according to the invention as originally defined in British Paters Application No. 8700269 also conform with the now delinition of fragments as set out herein and those fragments of sequences defined under (a), (b), (c) or (d) above which do not include the bases marked "" form a particular aspect of the present invention. Such fragments have sequences corresponding to at least a portion of the sequences.

a') GTG GGC TGG GGG GGC GGT GGA GCC

a'') CGG GGC CGG CCT GGT GTC CGG GGC CGA GGT GAC AC

b') DNA complementary to the sequence of a') or a"),

25

30

c') RNA having a sequence corresponding to the sequence of a') or a") and

d') RNA having a sequence corresponding to one of the complementary DNA sequences of b')

[0024] In the human genome the DNA tandem repeat sequence comprises antiparallel double stranded DNA, one strand having sequence (a) and being paired with a strand having sequence (b).

[9025] As mentioned above the nucleic acid tragments of the invention may be used as a probe for detecting one or other strand of the DNA tandem repeat sequence in the human genome, or RNA transcribed throm either strand and hence for identifying the gense or genes for human much core proteins, mRNA transcribed thereform and complementary DNA and RNA. For such purposes it may be convenient to use the complete normal gene comprising at least one another interest exquence, or mRNA transcribed thereform or to attach non-complementary fragments to either or both

unamount repeat sequence, or miniva transcribed therefore no to attach non-complementary fragments be either or both the S and S and soft a fragment according to the invention and/or to attach detectable belse (such as radiosotopoes, fluorescent or enzyme labels) to the probe or to bind the probe to a solid support. All of these may be achieved by conventional methods and the nucleic acid fragments of the invention may be produced do novo by conventional nucleic acid synthesis techniques.

50 [0026] The nucleic and fragments of the present invention may also be used in active immunisation techniques. In the such methods the fragment codes for a polyperbide chain substantially identical to a portion of the mucin core protein and may be extended at either or both the 5' and 3' ends with further coding or non-coding nucleic acid sequences and including regulatory and promoter sequences, marker sequences and picing or lighting sites. Coding sequences in the code for corresponding portions of the mucin core protein chain or for other polypertide chains. The fragment according frame register, into a suitable vector such as a plasmid or a viral genome (for instance vaccinia virus genome) and is then expressed as a polypertide product may be produced by culturing apprepriate cells transformed with a vector, harvested and used as an immunogen to induce active immunity against the mucin core protein. In another aspect the vector, paticically in the form of a virus, may be detectly innoculated thus a human or animal to be immunised. The vector then directs expression of the polypeptide in vivo and this in turn serves as an immunogen to induce active immunity against the mucin core protein to induce active immunity against the mediance proteins.

[0027] The invention therefore provides nucleic acid fragments as hereinbefore defined for use in methods of treatment of the human or animal body by surgery or therapy and in diagnostic methods practised on the human or animal

body. The invention also provides such methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practised in vivo as well as ex vivo and in vitro.

(0028) The invention further provides a polyaeptide comprising a series of residues encoded by the DNA tandem repeat sequence, he sequence shown at (f) above being the coding sequence. Polypeptides according to the invention are selected from any of those having 5 or more amino acid residues represented by the following amino acid sequence Val Th Ser Ala Pro App Thr Arg Pro Ala Pro GN Ser Thr Ala Pro Pro Ala Pro GN Ser Thr Ala Pro Pro Ala Pris GN Val Thr Ser Ala Pro App Thr Arg Pro Ala Pris GN Ser Thr Ala Pro Pro Ala Pris GN Ser Thr Ala Pro Pro Ala His GN Vermarks the start of the repeat in the perpole). Polypertiples according to the invention may have a sequence corresponding with any portion of the 40 residue sequence above and may include the start bord of the respeat sequence.

10 [0029] Other polypeptides according to the invention include three or more repeats of the 20 amino acid repeat sequence. Such polypeptides may include minor variations by way of substitution or individual amino acid orelutes. [0030] The invention further provides polypeptides as defined above modified by addition of N-acetyl galactosamino (a finlage sugar) on serine and/or three nine residues and by addition of oligosaccharide moieties to that or via other finlage sugars and/or transport linked to carrier proteins such as keyfole illignet hasomorpounia, abbumen or thypoglob-

[0031] Preferably the polypoptide comprises at least 10 amino acid residues of the sequence above, more preferably 20 residues. The polypoptide may comprise the full sequence above. Such polypoptides may further comprise additional amino acid residues, preferably conforming to the amino acid sequence of HPEM core protein.

[0032] In a further aspect the present invention provides the HPEM core protein. This is encoded by the PUM gene or an and we be produced by recombinant DNA techniques and expressed without glyceoptation in human or nor-human cells. Alternatively it may be obtained by stripping carbohydrate from native human mucin glycoprotein which listelf may be produced by isolation from samples of human issue or body fluids or by expression and full processing in a human cell line. The HPEM core protein may be used for raising antibodies in animats for use in passive immunisation, diagnostic tests and timour localization and in active liminusistion of humans.

25 [0033] The invention further provides antibodies (monoclonal or polyclonal), and fragments thereof, against ny of the polypetides described above. Such antibodies may be obtained by conventional methods and are useful in diagnostic and therapeutic applications.

10034] The invention further provides antibodies (noncolonal or polyclonal), or fragments thereof, linked to these poutically or diagnostically effective ligands. For therapoutic use of the antibodies the ignands are lothal agents to be delivered to cancerous breast or other tissue in order to incapacitate or kill transformed cells. Lethal agents include toxins, radioisotopes and direct killing agents' such as components of complement as well as crybtoxic or other drugs. Further therapouts uses of the antibodies inclusive passker immunisation.

[0035] The invention further provides therapeutic methods composing the administration of effective non-toxic amounts of such ambiodies or fragments thereof and ambiodies or fragments thereof for use in therapeutic treatment of the human or animal body. Especially in therapeutic applications it may be appropriate to modify the antibody byte coupling the 5th region thereof to the Foreignion distributions desired from the species to be treated (e.g. such that the Fabregion for mouse monocloral antibodies may be administered with a human Fc region to avoid immune response by a human patiently or in order to vary the isotype of the antibody.

[0036] In the diagnostic field the antibodies may be linked to ligands such as solid supports and detectable tabels such as enzyme labels, chromophores and fluorophores as well as radioisclopes and other directly or indirectly detectable labels. Preferably monoclonal antibodies or fragments thereof are used in diagnosts.

[0037] The invention further provides a diagnostic assay method comprising contacting a sample expected to contain abnormal human mucin glycoproteins with an ambody as defined above. Such methods include termoun localization involving administration to the patient of the antibody or Iragment thereof bearing a detectable label or of an antibody or fragment thereof and, separately simultaneously or sequentially in letter order a labeling enthy capable of selectively binding the antibody or fragment thereof. The invention also provides antibodies or fragments thereof for use in diagnostic methods practised on the human or arimals body.

[0038] Particular uses of the antibodies include diagnostic assays for detecting and/or assessing the severity of breast, ovary and lung cancers.

[0039] Diagnostic test titls are provided for use in diagnostic assays and comprise antibody or a fragment thereof, optionally suitable labels and other reagents and, especially for use in competitive assays, sundant down [0040]. The invention will now be illustrated by the following Examples and with reference to the figures of the accompanying drawings in which.

55 Figure Legends

[0041] Figure 1: Purification of the silk rucin by immunoaffinity chromatography using the antibody HMFG-1. Milks from several individuals were combined and absorbed to a HMFG-1-Sepharose column as described in Methods. The

material eluting at low pH was indinated and subjected to PAGE electrophoresis and autoradiography (track 1), The iodinated material was precipitated using the Protein A method with antibodies HMFG-1 (track 5), HMFG-2 (track 2), ST254 (track 3) and RPMI + 20% FCS (track 4).

[0042] Figure 2: Comparison of the 125t labelled purified milk mucin with immunoblot of human skimmed milk. A, human skimmed milk was subjected to SDS polyacrylamide electrophoresis, transferred to nitrocellulose paper, the blot probed with the monoclonal antibody HMPG-1 and binding detected using an ELISA method. B, after purification on an HMFG-1 affinity column followed by G75 Sephadex chromatography the milk mucin was indimated by the Bolton and Hunter method and subjected to SDS polyacrylamide electrophoresis and autoradiography.

[0043] Figure 3: Autoradiography of the iodinated milk mucin after treatment with hydrogen fluoride. The purified milk mucin was treated with HF for 3 hours at room temperature (track 1) or 1 hour at 4°C (track 2) and the resulting

preparations were then iodinated and run on SDS polyacrylamide gels.

[0044] Figure 4: Reactivity of the intact, partially stripped or extensively stripped milk mucin with indinated lectins. The purified intact milk mucin (track 1), the mucin treated with HF for 1 hour at 4°C (track 2) and the mucin treated for 3 hours at room temperature (track 5) were subjected to SDS polyacrylamide electrophoresis and then transferred to nitrocellulose paper. The paper was then probed with 125I PNA (peanut agglutinin), 125I WGA (wheat germ agglutinin), or 125| HPA (Helix pomatia agglutinin).

[0045] Figure 5: Immunoprecipitation and immunoblots of the partially and extensively stripped mucin. A, the 125] extensively stripped mucin was immunoprecipitated with SM-3 (track 3), HMFG-2 (track 2) or NS2 medium as a control (track 1) by the protein A plate method (see Materials and Methods). B, the partially stripped mucin (track 1) or extensively stripped mucin (track 2) was run on SDS polyacrylamide gels and transferred to nitrocellulose paper. The blot was then reacted with a cocktail of SM-3 and SM-4 monoclonal antibodies and the binding detected using an ELISA method

[0046] Figure 6: Reactivity of monoclonal antibodies SM-3 and HMFG-2 with methacam fixed breast tissue and tumour sections using an indirect immunoperoxidase staining method. Infiltrating ductal carcinoma showing strong reactivity with both SM-3 (A) and HMFG-2 (B). Fibroadenoma showing no reactivity with SM-3 (C) and strong heterogeneous staining of the epithelium with HMFG-2 (D). Papilloma showing very weak reactivity with SM-3 (E) and strong positivity with HMFG-2 (F). Both normal resting breast (G) and lactating breast (I) were negative when stained with SM-3, whereas both tissued stained positively with HMFG-2 with lactating breast (J) much stronger than normal resting breast (H).

Figure Legends

[0047] Figure 7. Periodic acid-silver stained milk mucin after antibody affinity column and gel filtration column. Milk mucin was purified on an HMFG-1 antibody affinity column (lane 1) followed by passage through a G75 Sephadex column (lane 2), subjected to NaDod SO4/polyacrylamide gel electrophoresis, and silver stained following treatment of gels with 0.2% periodic acid.

[0048] Figure 8. Silver stain of partially and totally stripped core protein from milk mucin. The purified milk mucin was deglycosylated by treatment with anhydrous hydrogen fluoride for 1 hr at 0°C (lane 1) and 3 hr at room temperature (lane 2), separated by electrophoresis through a NaDodSO₄/polyacrylamide gel (10%) and silver stained.

[0049] Figure 9. Immunoprecipitation with MAbs of in vitro translated protein products from MCF-7 poly(A)* RNA. Poly(A)* RNA from MCF-7 cells was translated in a rabbit reticulocyte tysate system (Amersham) in the presence of 195Simethionine (1000 Ci/mmole; 1Ci = 37 GBq) following the manufacturer's conditions. Samples containing 5 x 104 acid precipitable cpm were precipitated with MAbs SM-4 (lane a), SM-3 (lane b), HMFG-2 (lane c), HMFG-1 (lane d) and an irrelevant MAb to interferon (lane e, 24), separated on a NaDodSO_polyacrylamide gel (10%), impregnated with Amplify and erposed to IAR-5 film at -70°C for 20 days.

[0050] Figure 10. Immunoblot analysis of fusion proteins from the Amuc clones. The phage clones AMUC 3.4,6,7,8,9 and 10 were used to lysogenize bacterial strain Y 1089, Lysogens were grown at 32°C, shifted to 42°C, and then induced with IPTG. Lysogen proteins were fractionated by electrophoresis through a NaDodS0a/polyacrylamide gel (7.5%), transferred to nitrocellulose, and reached with HMFG-2. The binding was detected with an ELISA method using

4-chloro-1-naphthol as the substrate. The numbers are those of the λ clones.

[0051] Figure 11. Hybridization of pMUC10 to cDNA inserts of pMUC clones. DNA from the plasmid clones was digested with restriction enzyme EcoRI to excise the cDNA inserts, separated by electrophoresis on 1.4% agarose and transferred to Biodyne nylon membrane. The filter was hybridized using standard conditions (34) to the insert from pMUC10 which was labelled with [a:32p]dCTP by the method of random priming (41). Lanes: plasmid clones 3,4,6,7,8,9,10.

[0052] Figure 12. RNA blot hybridization analysis of mammary breast mucin mRNA. 10 µg of total RNA from human breast cancer cells MCF-7 (lane 1) and T47D (lane 2), normal human mammary epithelial cells HuME (lane 3), human embryonic floroblasts ICRF 23 (lane 4), Daudi cells (lane 5) and carcinosarcoma HS578T cells (lane 6) were separated

in a 1.3% agarose/glyoxal get, blotted on to nitrocellulose and hybridized to the pMUC10 EccRi insert which was labelled with [c.32p]aCTP by the method of random priming (41). The size markers were 28S (5.4 kb) and 18S (2.1kb) rRNAs.

| 10053| Figure 13. Polymorphic human DNA fragments descred by hybridization with pMUCI Oprobe. Genomic DNA samples repeated from the within blood cells from ten individuals (six unrelated) and from three cell lines were dipested to completion with Infliand EcoFII, fractionated by electriphoresis through 0.7% and 0.6% agarces, respectively, and transferred to Biodyria nyfor membranes. The filter was hybridized to the pMUCI DI DNA inner Whitch was balled with [a²⁰9[dCTP by the method of random priming (41). X-ray (film was exposed for 1 day at 70°C with intensitying scenera. Lanns 1-1 start, two daughters and mother, lanner 5-10 unrelated individuals, laren 11 is IMCF-7, laren 15 is ICRF-23. The DNA samples exhibit a wide distribution of sizes. Numbers indicate length of DNA in lb. The apparent banks at 286°B are in lans 1-2 and 13 are artisates introduced in autorationated in aut

Example 1

Purification of the milk mucin

[0054] The milk mucin was purified from human skimmed milk by passage through an HMFG-1 affinity cola followed by size exclusion chomatography. The HMFG-1 monoclonal antibody was purified from flase uculture supernatural using a protein A column (1). The purified antibody was coupled to cyanogan bromide activated sepharcas (Pharmacia) as described in the manufacturer's instructions. Human skimmed milk was passed in bacthes of 100 milk intrough the antibody column followed by extensive washing with PBS. Bound antigen was eluted from the column using 0.1 M givins pH 2.5 and the fractions registering an optical density at 260m wave pooled, claysed against c) 25 M acetic acid and yophilized. Eathers of about 20 mgs were dissolved in 0.25 M acetic acid and passed through a G75 sephader column (1 x 100 cm) which had been previously equiligitated with acetic acid. The outern was washed with 0.25 M acetic acid and not make the column of the color o

Deglycosylation of the milk mucin

10055] To remove the C-linked catobrtydrate from the milk mucin the molecule was treated with anhydrous hydrogen fluoride as described by Mort and Lamport (21), for either 1 hour at 4°C which produced a partially stripped preparation, or 3 hours at room temperature which produced the extensively stripped mucin.

logination of the milk nucin

[0058] Iodinations of the purified mucin, the partially or extensively stripped mucin were carried out using the Botton and Hunter method (51). Briefly, he mucin, 2.5 µg 102 µl c.1 Mb toxib buffer pt 6.8, was added to the dired Botton and Hunter reagent (1 mC). Amerikam international pt) and incubated at room temperature for 15 minutes. The reaction was stopped by the addition of 0.5 ml of 0.24 (by ptien inbroate) buffer and after a further 15 minutes incubation, free Botton and Hunter reagent was removed by passage through a G25 Sephadex column (PD10 columns, Pharmacia) previously equilibrated in PSS.

Iodination of Lectins

46 [0057] Wheat germ agglutinin (WGA), peanut agglutinin (PNA) (Vector Labs) and Helix pomatia agglutinin (HPA) (Boehringer) were iodinated as described by Karlsson et al. (52) using the chloramine T method.

Polyacrylamide gels and Western blots

90058] Polyacylamide gel electrophorasis and immunobiothing was parformed as described previously (1). Briefly, samples were run on 5-15% polyacylamide gels and then electrophoratically transferred to nitrocalulose paper (Schleicher and Schuell) at 50 volts overnight at 4°C (88). In the immunobiothing experiments the paper was reacted with nonoclonal artitlocides and binding detected with an ELISA method using 4-chloro-1-naphriad as the substrate. Por leach binding studies the Western blots were necated with the locinated leaches as described by Swellow et at. (48).

Production of monoclonal antibodies

[0059] A female BALB/c mouse was immunized with 5 µg of the partially stripped milk mucin in Freund's complete

adjuvant and 5 months later boosted with a further 5 µg of the same preparation in Freund's incomplete adjuvant. After a further 20 days, 5 µg of the mucin extensively stripped of its carbohydrate was given intervenously in saline solution. The spleen was removed 4 days later, and fused with the NS2 mouse myeloma cell line (53).

Screening of hybridoma supernatant and immunoprecipitations

[0609] The screening assay was a modification of that described by Malero and Genzalez-Rodriguez (54), Multived) plates were costed with 50 µl of 1.0 mg/ml protein A (Pharmaca). Fine Chemicals) in 1988 and allowed to 40 revernight at 3°°C. The plates were blocked with 5% 88A for 1 hour at 3°°C followed by the addition of 50 µl of rabbt anti-mouse immunoglobulin (DAKC, diluted 1:10 in PSB/SSA). After incubating for 2 hours at 3°°C followed with 5% 100 plates were washed twice with PSB containing 1% 86A and 50 µl of locinates incubated with 200 µl of school and containing 1.00,000 cpm added to each well. The plates were then incubated at room temperature for 4 hours, washed 4 times with PSB/SSA. and 50 µl of locinated partially stripped much containing 10,000 cpm added to each well. The plates were then incubated at room temperature for 4 hours, washed 4 times with PSB/SSA. and the individual wells counted in a gamma counter, for immunoprecipitation experiments 50 µl of SSE sample brifer containing difficient value and the bright of the same plates were then the wells which were than boiled for 3 minutes and the buffer loaded onto 5.15% polyvarnylamiding garderin gale.

Staining of tissue sections

20 [0061] Tissues from primary mammay carcinomas, benign breast biospies, normal breast, and pregnant lactaining breast lise; were fixed in mentucard mentance clostroform and acode acid 60 30-10) and embedded into paralfin wax. Sections were stained with the antibodies using the indirect peroxidase antiperoxidase method as previously described (47).

25 Results

Purification of the milk mucin

around 14K (figure 2B).

[0062] The milk mucin was purified from human skimmed milk on an HMFG-1 antibody affinity column. Indination of the elited material revealed the presence of a large molecular weight component and a SBKD band. Precipitation of the affinity purified material with antibodies HMFG-1 and HMFG-2 (tracks 2 and 5) followed by gel electrophorosis showed that both the high molecular weight components and the Self-10 component were precipitated by both antibodies (less effectively by HMFG-2). Since the GBKD component was also precipitated by two unrelated antibodies (figure 1, tracks 3 and 4) and this component was not widen on an immonibot of the purified material reacted with HMFG-15 (figure 2A), the 68K component was reword by molecules sieve chromatography on a 075 column. The final purified product showed a major high molecular weight band, with only a trace of the 68K component and an infor contaminant.

[0063] A high molecular weight glycoprotein (PAS-Q) containing more than 50% carbohydrate in 0-linkage has been purified from the human milk at globule by Shimiu and lamauschi [Q. 10 see whether this component was similar to the much isolated from milk by affinity chomadography on an HMFQ-1 affinity column, the animo acid composition of the purified HMFQ-1 reactive mount may addermined and compared to the animo acid composition of the purified PAS-Q and the muchine and compared to the animo acid composition of the purified PAS-Q and the muchine purified hera are the same.

45 Isolation of the core protein of the milk mucin

[0063] As there are no enzymes easily available that are efficient at removing 0-linked sugars, and § estimation often results in damage to the protoin core, the oligosaccharides were removed by treatment of the music with anhy-dross hydrogen fluorids. This treatment has been shown by Mort and Lampon (21) to be effective in removing sugars of trom pig submarillary mucin without damaging the protoin core. Amino acid analysis of the material protoides after HF treatment of the milk mucin suggested that the protoin core was also in this case undamaged, since the composition was the same as that seen in the intact mucin (Calbb 1).

[0065] Initially the milk mucin was exposed to HF for only 1 hour at 4°, but analysis of the product showed that there was only partial removal of the sugars with such treatment, and it was necessary to treat the mucin at room temperature for 3 hours to obtain a molecule which showed no leach binding ability. Figure 3 shows an autoradiograph of the iodinated products aftor treatment for 1 hour at 4° (track 2) or 3 hours at RT (track 1). It can be seen from Figure 3 that the middor treatment results in a mixture of products made up of high molecular weight material which is slightly emailer than the intact mucin and a number of smaller bands. After longer exposure to HF at town temperature, the high

molecular weight bands disappeared resulting in polypeptide bands of about 68KD and 72KD.

[0086] To test for the presence of sugars on the intact mucin and on the products produced after the two different. He treatments each preparation was subjected to actypatine go ellectrophoresis transferred to introcelliptice paper and reacted with 128-tabelloci factins. The factins used were peanual lectin (PNA) which neacts with palactose filined to Acady significant paper (MVAA) reactive with N-acotyl glastocoamine, whose gram (MVAA) reactive with N-acotyl glastocoamine, Playre 4 shows autoradiographs. Which reacts with the linkage sugar in O-finhed glycosylation. N-acotylogialactocamine, Figure 4 shows autoradiographs of the reacted blots, and it can be seen that while treatment with HF or It at 4° (tack 2) after the bettin reactivity of the mucin, carbotydrate is still present. Interestingly, however, there is a much lower level of binding of PNA to the high molecular weight malertain weight malertain weight mucin fracts. It

70 Moreover, this loss in PNA binding ability is a comparied by binding of the inkage sugar specific legin HPA. This lectin shows no binding at all to the intract mucin, and the changed pattern of lectin binding after limbed treatment with HI bindicates that sugars masking the O-linked Nacetylgalactosamine have been stripped oil. The smaller component seen in both the intact mucin (rack 1) and in the partially stripped preparation (rack 2) is a glycoproline which nearch with FGA, although not with PNA. This may correspond to the component of similar molecular weight (around 68E) seen after affirthy chromatography of the mucin and may receives and an intermediate be precursor molecular weight (around 68E).

[0067] Figure 4 shows clearly that the 68E and 72K components produced after extensive treatment with HF (3 h at RT), show no reactively with the locifics (fact &5), including the K-ackylgulatorisamin specific lecin HPA. This observation constitutes strong evidence that the segans have been removed from at least the majority of the molecules, and we will refer to this preparation as the extensively stripced music.

Generation of monoclonal antibodies to the milk mucin core protein

10068] A fusion was carried out using the spleen of a mouse that had been immunized with two injections of the parallally stripped milk mucin followed by a boost with the extensivity stripped minich. The clones were initially screened against the ¹⁰⁹ partially stripped material using protein A plates (see Methods). Four hybridomas were selected and cloned, and table 2 shows their spectrum of reactivity with the intact, partially and extensively stripped mucin. As can be seen from this table three of the hybridomas wich were isolated showed a strong reaction with they partially and extensively stripped mucin and did not react with the intact mucin. These appeared to be good candidates for monochonal antibodies to the protein core and two, SMA and SMA-4, were selected to be characterised further.

00099] It can also be seen from table 2 that the HMFG-1 and HMFG-2 antibodies reacted very strongly with the mucin stripped of its carbohydrate. These two antibodies were, in fact, developed using the intact mucin (from the milk fat globule) as immunospen and, in the case of HMFG-2, growing nammany epithelial cells (14). Their reaction with the stripped mucin was unexpected, as circumstantial evidence had previously led to the belief that carbohydrate might form at least part of their artipagenic optopes.

Molecular weight of molecules carrying antigenic determinants

[0070] The antibody, SM-3 was shows to be of the IgG1 subclass, while the SM-4 antibody was found to be IgM. We therefore chose to use the SM-3 antibody in subsequent experiments since antibodies of the IgM class can present problems in some applicable. Immunoprecipitation of the extensively stripped material with SM-3 showed a reaction with the lectin unreactive 68E component (Figure 5A, track 5). The monoclonal antibody HMFG2-Can also be seen to immuno precipate the lectin-unreactive 68E component (track 2). The antibodies were reactive with antipa on immunoblost and Picture SB shows the reaction of antibody SM-3 with the dominant 68K band of the extensively stripped music flutack 5.

45 [0071] We have previously shown that the molecular weight of the component in breast cancer cells carrying determinants found on the milk microin is bewer than 400K and can vary from one turnour to another (1). Reaction of antibody SM-3 with Western blots of gel separated extracts of breast turnour cells shows that this antibody reacts with components of similar molecular weight to those reactive with antibody HMFG-2 (data not shown). Because the antibody SM-3 differs from the antibodies of the that close not near that the than the much processed by the factating the state of the state of the think of the state of the think of the think of the state of the think of t

gland and yet reacts with molecules processed by breast cancer cells, it was appropriate to examine the reaction of SM-3 with a range of breast cancers.

Reactivity of SM-3 with breast tissues and tumours

[0072] The antibody SM-3 reacted with paraffin embedded tissues provided these were fixed in methacam (not formal saline). Using this method for preparation of tissue sections, the reaction of the antibody was compared to that of HMFG-2 or breast tissues and murours with an indirect immunoperoxidase staining method. This natysis showed a dramatic difference in the staining pattern of SM-3 compared to that seen with HMFG-2. Thus, although a strong

positive reaction was seen in 20/22 breast cancers stained with SM-3 (as compand to 22/22 stained with HMFG-2), normal resting breast, pregnant or locatating tissues and most benign lecions were largely unstained with SM-3 but were stained-with HMFG-2. Some examples of staining pattorns of breast tissues and tumours are illustrated in Figure 6. (D072)] Twonty-two primary carcinomas and fourteen benign lesions were examined and the reaction of SM-3 compared to the staining with HMFG-2 in each case. In the primary carcinomas, staining with SM-3 was heterogeneous but generally uplies trong and always confined to tumour cells; connective tissue and stroma showed or neaction (see figures 6A,B). In the four fibroadenomas examined, staining of the spithelium with HMFG-2 was strong athough neterogeneous. In comparison, staining with SM-3 was negative in one case and in the three others staining was confined to only one or two glandular elements. HMFG-2 showed strong postitivity on the five papilipmas and five cases of cystic lessaes studied while the staining observed with SM-3, was very much weaker and more haterogeneous (Figures 6A, H). The papillomas as a group showed the strongest staining with SM-3, and it can be seen that the staining was membranous or extracelular.

10073| In contrast to HMFG-1 and HMFG-2 which strongly stain lactating and prognant breast, SM-3 was totally negative with three out of six cases of pregnant or locating breast (see figure 90 and 10). Two positive cases showed only very weak staining of an occasional cell and in the third, staining was confined to two areas of one lobule. Again, contrast to HMFG-1 and HMFG-2 which do reast with some terminal ductal flobule with set of mornal, resting breast (albeit weakly), SM-3 was totally negative on eight out of the thirteen cases issued and in the other five cases staining was extremely weak and often confined to one or two achini the disease section (see figure 6E and F). It should perhaps be noted that the intensity of staining with HMFG-2 seen with normal breast issues and bonign lesions fixed in meth-acam was somewhat higher than that reported previously using formatin fixed makerial (50,47).

10075] SM-3 wat also shown to be negative on sections of normal liver, lurg, thyrmus, sweat gland, spititymus, prostate, bladder, mall intestine, raign intestine, appendix, thyroid and skin. The arthbody showed weak positive staining only with the distall tubules of the kidney, the occasional chief cell of the stomach, the occasional duct cell of the salway olderal and the sebaceous cland.

Discussion

25

[0076] Large motecular weight mucin motecules are expressed by many carcinomas and carry many of the tumour associated artifacine determinants recognised by monoclonal antibodies. These géptices may also be expressed by some normal epithelium, and some monoclonal antibodies like HMPG-1 react particularly well with a mucin found in normal human milk (1,17). As long as the study of the mucins is restricted to their detection with antibodies reactive with undefined epicipes, the knowledge of their structure, expression and processing will also be restricted. We have begin to investigate the structure and expression of the mammany mucin by isolating the core protein and developing antibodies which have allowed as to select partial cDNA clones for the gene coding for the core protein. This Example describes the production and characterization of these artibodies.

10077] Treatment of the HMFG-1 affinity purified milk mucin with hydrogen fluoride resulted in the appearance of a dominant band of about 88E dations and a minor species of about 72KO on SDS acrylamide gels; These bands showed no reactivity with leafins, including Helix pomata agglutinin which is specific for N-acety gladiclassamic, the first sugar or clarked glycosylation (55). It therefore seems probable that this 68K dation polypeptide represents the corp protein of the mucin. Supportive evidence for this somes from the observation that the antibodies described here, which are reactive with the stripped 68K component, can precipitate a molecule of this size from the in vitro translation products of mRMA soldard from breast cancer cells expressing the mucin.

[0073]. As the milk mucin contains at least 50% cathohydrate (16), a protein core of only 68KD appears too small if the intact molecule has an observed molecular weight greater than 400KD. However, mucins can be composed of small subunits which aggregate and are held togularly by some form of non-covalent interactions, as yet not understood. For example, although the molecular weight of the owine submaxillary mucin has been reported to be greater than 1 x10° datons (46), it has a protein core of only 650 amino acids with a molecular weight of 53.00 dations (46).

[0079] An unexpected finding was that the antibodies HMFG-1 and HMFG-2 which react with the milk mucin, also show a positive reaction with the extrestlyed stripped material which showed no location binding capability. Previous indirect evidence, including the resistance to fixation, boiling and reduction, the repetitive nature of their epilopes and the appearance of several bands on immunoblost, had led to the belief that catchydrate present on the milk mucin was twolved in these epilopes. This idea was reinforced by the observation that lectins could block the binding of HMFG-1 and 2 (1). While it is not possible to would be the possibility that some sugars, undersided by the lectin binding experiments, emain on the extremelyed singled mucin described not, his is unifiely to be the explanation for the reactivity of the authorised HMFG-1 and 2. This can be said since both antibodies have recently been shown to react possiblely with Pspatiocidised subson proteins expressed by phage carrying DNA coding for the core protein of the mammary mucin. It appears therefore that at least part of each of the epilopes recognised by HMFG-1 and 1 HMFG-2 contain amino acids but in much be assumed that some of these epilopes on the core protein are represent, is not

Basked in the fully glycosylated molecule. The HMFG-2 epitope is however leas abundant on the milk mucin than the HMFG-1 epitope, while it is readily detectable on the mucin molecules expressed by tumours (1). These molecules have a smaller molecular weight and may be less having dycosylated or polymerized.

- [0000] Here we have reported the development of new artibodies which are reactive with the protein core of the much and with the partially elopycey lated molecule, but with a reu meactive with the light processed much in protein do by the lactating mammary gland. One of these artibodies SM-3, which is an 1gG1, has been studied in more detail. It has been shown to react with the much molecules which are proteined by threat cannot credit and are recognised by many antibodies developed against the intact milk mucin. It should be emphasized however that the epitope recognised by SM-3 which is on the core protein and is exposed on the mucin as processed by tumour cells, is not exposed on the normal processed milk mucin. This feature offers the possibility of enhanced tumour specificity, and a pilot immunihation contact study of breast unmours and tissues has shown that indeed the SM-3 ambidy varies the torilly with the majorly of primary breast cannours (91%) but shows little or no reaction with benigh breast tumours, resting or lactating breast, and most rormal tissues.
- (5081) There are several implications of the work described here which may be important for both basic and clinical studies in the weat cancer. The observation that parts of the core protein (detectable by amthodise) are exposed on the mucins as processed by breast cancer but masked on the mucin as processed by cells in normal breast and benigh tumours implies that there is an abration in the processing of the mucin in matignancy. A more detailed study of the processing of the mucin in normal and malignant cells may then give basic information for defining the matignant cells may then only one basic information for defining the matignant cells may then one of the cell of the matignant cells may then one of effective diagnostic tool for the delection of breast one of the cell of the cells of the cells of the delection of breast one of the cells of t
- cancer cleik in tissue sections, tissue fluids and cells. The reactive components are nembrane associated as well as intracellular and in vivo localisation of tumours may also be possible.

Abbreviations

25

[0882] The abbreviations used are: HMFG, human milk fat globule: PBS, phosphate-buffored saline (153 mM Nacl, 3 mM KCL, 10 mM Na₂HPO₄, 2 mM KM₂PO₄, BH 7.4]; WGA, wheat germ agglutinin; PNA, peanut agglutinin; HPA, Hofix pomatia agglutinin; SPA, bovine sorum abbumin; SDS, sodium dodecyl sulfate.

Example 2

- [0083] Purification and deglycosylation of human milk mucin was conducted as in Example 1 mucin was purified on an HMFG-1 antibody.
- [0084] The stripped mucin preparations were separated by electrophoresis through NaDodSO₄/polyacrylamide gels (10%) and silver stained by two methods, one of which can be used to stain highly glycosylated proteins (22,23).

Preparation of polyclonal rabbit antiserum to stripped core protein

[0085] One New Zealard White rabbit was immunited with 100 µg of the partially stripped core protein in compisto or Frendrick adjuvant (Glicko). Boster irripetions of Fologo µg of the totally stripped core protein were administered in incomplete Freund's adjuvant (Glicko) 3 and 4 weeks after the initial injection and the rabbit was bed one week tater. The microfilers of immune serum (Fig. 9µm) proteinj precipitated 200 ng of thely stripped core protein in a Frenian A assay (24) and detected it on immunobiotis. The immunopidotian fractions of rabbit pretimeter and tabbit anti-mucin core protein was represented by adding ammonium sultate to 50% saturation. The resulting pellet was resupposed in one-shall the original serum volume of PBS and dialyzed against the same buffer. After dialysis, only residual precipitate was resupposed by certifugation, immunopidotian fractions were stored in allocate at 250 millions.

Description of MAbs used

- 90086 In addition to the polyclonal artisenum used for initial screening, a cocktail of two MAbs, S.M.3 and SM-4 (see Example 1) which recognise the mucin core protein (20) and HME-61 and HME-62. (1.4) where used to screen the purified plaques, the f-galactosidase used for immunopsecipitations from in vitro translated proteins: . Other MAbs used were a monochoral antife plaglactosidase artibody (25) which was a gift from H. Durbin (IRBF, London), an anti-inferior on mithody, ST254 (24), LE61, a keratin antibody (25) and M18 which recognizes a carboly-57 drate structure on the mith such (27).
 - The MAbs SM-3 and SM-4 (SM refers to stripped mucin) show strong reactivity with the partially and fully stripped core protein but no reactivity with the fully glycos/lated mucin (20).

In Vitro translation of proteins

[0087] FNA was isolated from the human breast cancer cell line MCF-7 using the guantisum isothicyanaler method of Chirgwin et al. (28) and poly(A)* RNA was purified by chromatography using oligo (dT)-cellubose (New England Bio Labs). The poly(A)* RNA was translated in a reticuloryte lysate system (Amerstran) in the presence of (*93) methionine (1000 Chimnole; 1 Ci = 37 GBs, Amersham). Samples containing 5 x 10° acid insoluble com were precipitated in a protein in Assay (24) using MASe SM4_SM4_ HMF-61, HMF-C2 and a control antibody to furnan inferioren. The antibody-selected proteins were then separated on a 10% NaDodSO_x/polyacrylamide gel, impregnated with Amplify Amersham) and excessed to IAR-5 film (Kodabl 1 x 70°C.

Antibody screening of Agt11 library and protein blotting

10088] The Ag11 library used in this study was constructed from mRNA isolated from the human breast cancer cell isom MCF-7 and was generously provided by Philippe Nather and Plear Chambon (Strabboury, France). The poly (A)¹ RNA used for the preparation of the randomly primed Shary was prepared from mRNA that sedimented faster than 858 rRNA and was enriched in extrogen recoptor (92). The library was made essentially as described by Hyphro et al. and Toung and Davis (30-32) and contained approximately t x 10⁶ recombinants per µg of RNA. Between 85% and 95% of the plaques contained inserts.

[0089] The phage library was plated onto bacterial strain Y1000 and grown for 8 ftr at 4PC. After isopropy I, P.D. Hiopathacisks (IPTS) induction and 8 hr of grown 4 37°C, Ribre were prepared from each plate and screened with anti-mucin core protein ambody by the method of Young and David (23). The first artibody used is screened with anti-mucin core protein ambody and protein prepared as described above. Prior to use in screening, whe after arbidit artifestor misted against the stripped core protein prepared as described above. Prior to use in screening, whe anti-early testa was not found to be necessary. The introduction filters (Schlacher and Schuell) were blooded by incubation IPSS containing 5% SSA for 1 hr at room temperature with grofits agitation. The filters were incubated at room temperature overright with a 1200 dilution of antisenum in heat smalled plastic bags. The filters were incubated at room in PSSISSA, and bound antibody was detected by using horisonated by providings antisenum in PSSISSA, and bound antibody was detected by using horisonated by providings or anti-early antisenum in PSSISSA, and bound antibody was detected by using horisonated by the filters were sub-school for the providing and purified through the SSISSA and the providing of the providing of

[0000] To examine the G-galactesidase-CDNA fusion proteins for immunoreactivity, cell systates were derived, Lysopens were propared as described in Young and Oavi (34). Cells were politated, suspended in Learnnis cample buffer (36) and separated by electrophoresis through NaDodSC-polyacrylamide gels (10%) and transferred onto nitrocellulose filters as described (13,6). The filters were treated as above for antibody sceeming.

Northern Analysis

9 [0011] RNA was isolated from lissue culture cells and frozen tissues by the guanidinium isothic/yanata method of Chirgwin et al. (28). Total RNA (10 per larne) was denatured by heating at 55°C for 1 in indicionized glyocal and fractionated by electrophrores through a 1.3% glyoxal gel (28). The RNA was transferred to introcellulose (Schleicher and Schwell), prohybridzed and hybridized as described by Thomas (34). Filters were warhed down to 0.1% SSC with 0.1% SDS at 65°C and exposed to XARA-5 lift (Gods) at .70°C with intensifying screens.

Southern analysis

[0082]. High molecular weight genomic DNA was prograted from white blood cells and cell lines (99.40). These genomic DNAs (*Opg) were classed with restriction enzymes following the manufacturer's recommended conditions and fractioned through 0.6% and 0.7% agarose gels. Cloned plasmid DNA was classed and fractionated on 1.5% agarose. The gels were denatured, neutralized and transferred to right membranes (Biodyne) according to the manufacturer's instructions. The EcoR1 insert from pMMCIO was separated on a 1% to write method point agarose (Biorand) gel and labelled with [e-279]cCIT by the method of another priming (14) and hybridized to filters at 42°C. Filters were washed down to 0.1% SSC with 1.0% SDS at 55°C and exposed to FARS Filter (Ecodá) at 27°C with intensitying screens.

Results

Purification and deglycosylation of mucin glycoprotein

9 [0033] Murin glycoprotein neactive with the monoclonal antibody HMFG-1 was prepared from pooled human breast mits by using an HMFG-1 antibody affinity column, followed by molecular since chromatography on Sephados (475 in order to remove lower molecular week) recomponents (Figure 7, lane 1), In order to demonstrate the homogeneity of the purified modeule, amino acid analyses of four separate preparations were performed and revealed a fairly, consistent composition with serine, threonine, proline, alaxine and glycine accounting for 58% of the amino acids. Periodic acid sliver stained gets revealed a diffuse band of greater than 60,000 dathors visible only when the get was treated with periodic acid fairly serine figure 7, lane 2). No other lower molecular weight bands were visualized on the cell using the silver stain (Fig. 7, lane 2). No other lower molecular weight bands were visualized on the cell using the silver stain (fig. 8).

[0094] The purified material was subjected to treatment with hydrogen fluoride to remove the O-linked sugars that are characteristic of mucin glycoproteins. Two different reaction conditions were used which resulted in a partially deglycosylated core protein (treated at O'Crior 1 in) and a fully deglycosylated core protein (treated at the Crior 1 in) and a fully deglycosylated core protein (treated at the core memperature for 3 hr) as determined by indinated lection binding following separation by gel electrophoresis and transfer to nitrocell-ulose paper (CD). The partially deglycosylated orce protein was reactive with what gram agglution, peant agglution and helk pormatial bottin (which recognizes the finkage sugar N-acuty[galactosamine) whereas the fully stripped protein showed no reactivity with any of these three flucities.

[0095] The hydrogen fluoride treated core protein was separated by electrophoresis through NaDocSCQ/polyacpy, lamide gole (10%) and silver statined. Silver staining revasaled that the prodominant component of the partially stripped mucin was a high molecular weight band of about 400 kd, although fairh bands of lower molecular weight could also be observed (Figs., lam 1). Since the high molecular weight material showed a somewhat increased mobility in the gel and reacted with the lectin recogniting the linkage suges, it can be assumed that some sugars had been removed. The fully stripped mucin consisted of two bands of about 68 bd and 72 kd (Fig. 8, lames).

Antibody reactive proteins produced by MCF-7 cells

[0096] The MCF-7 broast cancer call line expresses large anounts of HMFC-1 and 2 reactive material on its cell surface (14) and was thus juriged to be a suitable source of mRNA for a CNN silvary, Before proceeding to screen the MCF-7 library with the monoclonal antibodies, they were tested for their ability to precipitate a component from in vitro translation products produced from MCF-7 mRNA. Poly (14) FNN from MCF-7 was prepared and translated in vitro. Proteins from the translation reaction were immunoprecipitated using the monoclonal antibodies HMFC-1, HMFG-2, SM-3 and SM-4 and displayed by polyacythmide goel electrophoresis and fluorography (Fig. 3). Two proteins of second HMFC-3 (and SM-4 manufaced by SM-3) (and PS) and SM-4 (and FI). It was also found that HMFC-1 (and SM-4) mirrolavant monoclonal artibody to human interferon (and S). The fact that HMFC-1 and -2 immunoprecipitated these proteins was an unexposected inding as it was previously thought that these MAbs recognise carbody/drate does not be a substantial or the substantial control of the sub

that the epitops for HMFG-1 and -2 are, at least in part, protein in nature.

[0097] The abundance of the core protein mRNA in total cellular poly (A)* RNA was 4% as estimated by comparing the amount of (355)methionine present as immunoprecipitated protein to the amount of methionine incorporated into total protein during in vitro translation.

Screening of the cDNA library

45

[0098] The Agt1 cDNA library made from size solicated MGF7 mRNA (see Methods) was screened initially with the polyclonal aritherum made to the mucin core protein which had been stripped of its cutbohydrate. Screening of 2 x 10° plaques resulted in 11 positive clones, 7 of which were taken auccessfully through two further rounds of plaque purification.

10069] To demonstrate that the reactivity of the phage clones with the artitioody probes was due to arrigenic determinants on the CDNA translation product, β-galactosidase fusion proteins were made from all 7 clones. The proteins were separated by electrophoresis, transferred to nitrocellulose paper and probed with a variety of antibodies to the stripped mucin, including the polydenal antiserum which was used initially to select the clones and a cocitatiol of SM-3 and SM-4. In addition, HMFC-1 and HMFC-2, the two monoclonal antibodies which originally detected this differentiation and tumour-associated epithelial mucin (1,14) were tested. All 7 clones yielded fusion proteins which were specifically recognized by the polycolonal antiserum, the monoclonal cocktail, and HMFG-2, HMFC-1 antibody reached

with 6 of the 7 fusion proteins and failed to recognize the protein from clone 9 which contains the smallest insert. In every case the strongest signal was given by the MFCP-2 antibody and this reaction is shown in Figure 1.0 Monoclonal antibodies to keratins and to a carbohydrate epitope on this fully glycosylated much were used as controls and showed no reactivity A monoclonal antibodies was a positive control and the band recognized of the specific antibodies. The sizes of the fusion proteins varied in proportion to the sizes of the CDNA inserts found in the baseferichnase.

Characterization of cDNAs and RNA blot analysis

[9109] The insents from the 1 clones were designated pMLC3-10 (emitting pMLC5) and were subcloned into the vector pLC8 of reaster manipulation. The 7 clones were compared to each other for sequence homology. Each of the plasmids was digested with EcoR1 and the insent separated on a 1.4% agarcee get. The largest cDNA insent from pMLC10 was used to price be in sents and found to hydridze to all insents (Fig. 1), MMLC7 was about of cordain two insents solitowing dispession with EcoR1; however, only 1 of the insents hydridzed to the pMLC10 probe. The insent shards were not ordived from plaseg DNA since the PMLC10 probe for the pMLC10 probe in the pMLC10 probe in

[9102] Because the JAMIC clones were identified only by antibody binding, we needed additional assurance that yewer indeed coding for the treast ephtholia mucin. To determine the authenticity of pMILC10, we correlated the presence of mRNA hybridizing to the clone with mucin expression in various cell lines. As shown in figure 12, the cDNA hybridized to two transcripts of 4.7 bb and 6.4 kb in the RNA from the breast carefree cell lines MCF_2 and 17D which were shown previously to express the HMFG-2 antigen (1,14). Significantly, the pMIUC10 probe hybridized to transcripts of approximately the same size in RNA streams climps on normal mannay sphelial called Loutrad from milk (29). A third band of 5.7 bb can be seen in the RNA from these normal cells. In contrast, three human cell types that lack the mucin, breast fibroblasts, Daudi cells and HSSP18, a carriorisactroma like devived from breast tissue (49), showed no detectable pMIUC10-melated mRNA. The 6.4 kb band appears to be the most adundantly expressed. The presence of at least wow sizes of mRNA from MCF-2 cells correlates with the immunoprocipation of two proteins of (molecular weights 68 kd and 62 kd) from in vitro translated mRNA from MCF-7 cells. The normal mammary ephthelial cells were derived from cooled milk samples and the additional transcript deserved may be even to pylomphisms among individual transcript deserved may be even to pylomphisms among individual transcript deserved may be even to pylomphisms among individual transcript deserved may be even to pylomphisms among individual transcript deserved may be even to pylomphisms among individual transcript deserved may be even to pylomphisms among individual transcript deserved may be even to even the contrast transcript manufacture.

Genomic DNA blot hybridization and detection of a restriction fragment length polymorphism (RFLP)

[0103] Genomic DNA was prepared from a panel of ten Individuals consisting of six unrelated individuals and a family of four, and from three cell lines. The DNAs which were digested with Hird or EcoRI and blotted and hybridized to the radiobabelled pMILCY 01 insert, exhibit restriction fragment length polymorphisms. The restriction fragments from the ten radiobabelled pMILCY 01 insert, exhibit restriction fragment length polymorphisms. The restriction fragments from the ten individuals and three cell lines are shown in figure 13.1 hap pattern consists of either a single-band or a collect of sizes ranging from 3400bp to 8200bp in the Hirtl dipast with the exception of the 2775-1 DNA in lane 12, figure 13.4 which shows three bands of ror fines 200bp to 9600bp in the EcoRI dipacet (Figure 13B). There appears to be a continuous distribution of the fragment sizes which implies a high in vivo instability at the locus. The pattern of fragments observed in the family of four (fines 1-4) suggests that these fragments are allice. Preliminary studies of the DNA made from white blood cells of normal, related individuals indicate the exitance of a marriber of independent alleles with an autosemal confinent mode of the infertion. These studies will be the subject of a segarate investigation.

Discussion

[0104] The cDNA chones described here which were obtained from the MCF-7 \(\lambda\)gt11 library were selected using polyclonal and monodian antibodies prepared against a normal cellular product, the milk much in its deglycosylated form. This was done because it was easier to bother large quantities of the much for stripping than to prepare similar quantities of immunologically related glycoproteins expressed by breast ceneer cells (44). The fact that the antibodies dis select for CDNA coding for nonglycosylated orce protein molecules in MCF-7 cells, strongly suggests that the glycoproteins in these cells, which were originally detected by their reaction with artibodies to the milk much, contain the same core protein as this much. This is confirmed by the detection of mRNAs of approximately the same sixes in the normal and malignant colls, using one of the probes is colated from the MCF-7 library. We will therefore refer to the artibody reactive by corporation or broast cancer coles as mucins, bearing in mind that their processing may be different resulting in molecules of different molecular weights but with the same core protein as that of the milk mucin. [0105] Seven clones were obtained from the MCF-7 library of which the largest was 1600Ms. This cloner cross hybridizing almoduciones colones were obtained from the MCF-7 library of which the largest was 1600Ms. This clone cross hybridizing almoduciones were reactive with the polycholal adaptish mucin corporation as well as with low manda clones were reactive with the polycholal adaptism mucin corporation as well as with low manda clones were control or with the polycholal adaptism mucince corporation as well as with low.

well-characterized monoclonal antibodies directed to various spitces on the stripped core protein, SM-3, SM-4, HM-FG-1 and HMFG-2 (14,20). The smallest lambda clone, MMUC9, produced a p-galactosidase fusion protein which reacted with three of the four monoclonal antibodies and with the polyclonal antiserum.

[0108] The surprising result that the extensively characterized HMFG-1 and HMFG-2 noncolonal antibodies nearcles strongly with the lambda plaques and the fusion provies and could immunoprocipitate proteins from In_wity translated entering the provides strong evidence that these clones do indeed code for a portion of the nuclin core protein. Although provides strong evidence such as resistance to fixation, brilling, treatment with chitarhirol and NaDedSQ, and the presence of multiple epitopes on the molecule suggested that these were carbotydrate (1), it has now been established that the presence of multiple epitopes on the HMFG-1 and HMFG-2 monoclonal artibodies are definitely protein in nature. Carbotydrate may be required to obtain the strongest binding, where as part of the epitope or by conferring some conformational change on the protein portion, but part of the antigenic destrainant must consisted on a marine caid septiopence. Since these two MABs are reactive with the fully glycosylated mits mucin as well as the stripped core protein, this data means that the intact molecule contains areas of nated popitide which contribute to be antigenic estertor these two articles to extensions.

[0107] Confirmatory evidence that pMLC10 codes for the mammary mucin core protein in provided by RNA blost. The relative abundance of mRNA in the breast cancer cell lines MCF-7, 1470, 27-57-5 and in normal mammary epithelial cells corresponds to the artispen expression by these cells as measured by the binding of the HMFG-1 and HMFG-9 monochronal antibodies. Cell types which are negative for antigen expressions such as human fibroblusts, Quadi cells and HSS781, a carcinosascoma line derived from breast [14], as negative in RNAb both yelridizations. A fortulous observation made with the ZR-75-1 cell line, which routinely expressed in age amounts both of nRNA and antigen, yielded one preparation of RNA which was unexpectedly negative by both tybridization. It was subsequently found that those particular ZR-75-1 cells from which the RNA had been made had lost the expression of the artispen as well at this tine (as determined by reaction with HMFG-1 and 2). Different passage numbers of the ZR-75-1 cells were recovered and shown once again to express both antigen and meassage. The sizes of the message, 4.7 bb and 6.4 kb, are quite large, since a 68 kd or 82 kd pretein would need only about 3 kb to code for the protein portions. This suggests that a large portion of the mRNA and apply ourtransitated (Efforts are undewayn to total an affile-legit clone.

[0108] Thus, the cDNA clones presented here represent a portion of the gene coding for the human marmary much which is expressed by differentiated breast tissue as well as by most breast cancers. The major proteins procipated from in vitro translation products of RNA from MCP-7 colls by artibodies to the milk mucin core protein (68Kd) have an apparen, molecular weight of 88Kd and 98Kd. These proteins, produced by this breast cancer cell therefore share splopes with the 68Kd core protein of the milk mucin (20). Whether a similar 92Kd protein is also proteined by normal mammary epithelial cells, and is truncated or destroyed by HF reatment is not yet class. MCP-7 cells biosynthetically babilised with 14C amino acids yield upon immunoprecipitation with HFG-1 and HIMF-G2 antibodies, two glycopylated proteins of 220 kd and 430 kd, and it is possible that each of these glycoproteins utilizes only one core protein of either proportions or variably glycosylated. Further screening of the biorary may yield full length cDNAs coding for both sizes of the immunopolicially related core proteins. Since there appears to be only a single gene (based on Southern blot data obtained by using a partial cDNA protein, it is probable that the multiple messages arise by alternative (RNA splicing and this would explain the fact that they contain common sequences. Although a core protein of 88 kd appears to be

se small to yield a fully glycseylated molecule of greater than 300 kd which contains 50% carbohydrate, there is evidence that such a structure for mucinis is possible. Owns exhamisting mucin has a reported molecular weight of 1 x 10% dations (45), yet its protein core consists of 650 amino acids resulting in a molecule of 58 kd (46), [0109]. The mucins which are detected with HHIFG-1 and HHIFG-2 MAbs on immunobles of tumours and breast cancer cell lines show variations in size from 80 kd to 400 kd in the molecular weight mucins present in normal urine, a polymorphism has infeed been shown to be genetically determined (45). Although the very low molecular weight mource size sixely to represent precursor forms of the mucin which appears to be incompletely processed in many tumour cells (20), the variations in the sighter molecular weight components are slikely to the quantitations in the sighter molecular weight components are slikely to the due to this genetically determined protein or to the carbohydrate portion of the mucin. The detection of restriction fragment length polymorphism in the Southern states.

blotting experiments using the mucin probe suggest that the mucin polymorphism occurs at the level of the DNA which codes for the protein. Preliminary sequence data Suggest that the basis for this polymorphism is a region of variable tandom repeats present in the protein coding sequences. This structural feature may be reaponable for the generation of the many allelic restriction fragments at the mucin locus. We are presently investigating the basis of the mucin polymorphism by a Southern biot survey of DNA from while blood cells of normal, related individuals whose inheritance pattern of uniformly mucins has been determined. In addition, we are examining DNA proparations made from the white blood cells and tumours of individual breast cancer patients to determine if there is any discordance between genotype in the paired samples, since tandomly propared DNA may provide an unstable site where recombination or amortification.

could occur.

[0110] The prosence of mucins in the majority of carcinomas and their association with the differentiation of mammary epitholial cells makes it particularly important to identify regions involved in the tissue specific and developmental regulation of the gene. Moreover, the introduction of a functional mucin gene into cells should provide insights into the role of this molecule in breast epithelial differentiation and possibly enable us to identify any alterations in the function or expression of the mucin which are related to malignant transformation in the human breast.

Abbreviations

45

50

55

[0111] The abbreviations are as follows: PBS, phosphate-buffered saline; MAb, monoclonal antibody; IPTG, isopropyl β-D-thiogalactoside; bp, base pair(s); Kb, kilobase(s).

TABLE 1

		INDLL				
Amino acid composition of the human milk mucin - comparison with PAS-0						
Amino acid	HMFG-1 purified milk mucin	Extensively stripped milk mucin	PAS-0 (Shimizu & famauchi 1982			
Asp	6.1	7.2	6.4			
Thr	9.4	9.7	9.8			
Ser	9.1	13.0	13.1			
Glx	6.3	9.6	8.3			
Pro	14.8	14.4	12.0			
Gly	8.1	10.1	12.2			
Ala	12.3	11.9	13.0			
Cys Val	Not analysed	Not analysed	0.5			
	6.0	6.3	5.3			
Met	0.5	0.4	0.8			
He	1.6	1.7	1.9			
Len	4.5	4.8	3.7			
Tyr	2.0	0.9	1.6			
Phe	2.0	1.6	1.7			
His	3.2	2.3	3.8			
lys	2.8	5.3	2.2			
Arg	4.0	4.0	3.9			

Table 2

	125) cpm bound			
Antibody	Intact molecule	Partially stripped mucin	Totally stripped mucir	
5.17	8,524	11,925	5,780	
9.13	525	3,000	3,328	
SM-3	465	15,414	9,200	
SM-4	816	16,750	9,561	
HMFG-1	32,000	33,768	9,494	
HMFG-2	29,500	29,230	15.832	
NS2 medium	397	845	650	

[0112] The binding of the antibodies to iodinated intact, partially end totally deglycosylated milk nucin was assayed using the protein A plate method as described in Materials and Methods.

References

[0113]

5

10

- Burchell, J.M., Durbin, H. and Taylor-Papadimitriou, J. (1983) J. Immunol. 131, 508-513.
- 2. Bramwell, M.E., Bhavanandan, V.P., Wiseman, G. and Harris, H.
 - (1983) Br. J. Cancer 48, 177-183.
- 3. Mc Ilhinney, R.A., Patel, S. and Gore, M.E. (1985) Biochen. J. 227, 155-162.
- 4. Hilkens, J., Buijs, F., Hilgers, J., Hagemann, Ph., Calafat, J., Sonnenberg, A, and Van der Valk, M. (1984) Int. J. Cancer 34, 197-206.
 - 5. Tagliabue, E., Porro, G., Barbanti, P., Della-Torre, G., Menard, S., Rilks, F., Cerasoli, S. and Colnaghi, M. (1986) Hybridoma 5, 107-115.
 - 6. Johnson, V.G., Schlom, J., Paterson, A.J., Bennett, J., Magnani, J.L. and Colcher, D. (1986) Cancer Res. 46, 850-857.
- 16 Sekine, H., Ohno, T. and Kufe, D.W. (1985) J. Immunol, 135, 3610-3615.
 - 8. Ormerod, M.G., Steele, K., Edwards, P.A.W. and Taylor-Papadimitriou, J. (1984) J. Expt. Path. 1, 263-271.
 - 9. Wilkinson, M.J., Howell, A., Harris, J., Taylor-Papadimitriou, J., Swindell, R. and Sellwood, R.A. (1984) Int. J. Cancer 33, 299-304.
 - 10. Kufe, D., Inghirami, G., Abe, M., Hayes, D., Justi-Wheeler, H. and Schlom, J. (1984) Hybridoma 3, 223-232. 11. Price, M.R., Edwards, S., Robins, R.A., Hilgens, J., Hilkens, J. and Baldwin, R. (1986) Eur. J. Can. Clin. Oncol.
 - Johnston, W.W., Szpak, C.A., Lottick, S.C., Thor, A. and Schlom, J. (1985) Cancer Res. 45, 1894-1900.
 - 13. Rasmussen, B.B., Federsen, B.V., Thorpe, S.M., Hilkens, J., Hilgers, J. and Rose, C. (1985) Cancer Res. 45, 1424-1427.
- 25 14. Taylor-Papadimitriou, J., Peterson, J.A., Arklie, J., Burchell, J., Ceriani, R.L. and Bodmer, W.F. (1981) Int. J. Cancer 28, 17-21.
 - 15. Burchell, J., Wang, D. and Taylor-Papadmitriou, J. (1984) Int. J. Cancer 34, 763-768.
 - 16. Shimizu, M. and Yanauchi, K. (1982) J. Biochen, 91, 515-519.
 - 17. Ormerod, M.G., Steele, K., Westwood, J.H. and Mazzini, M.N. (1983) Br. J. Cancer 48, 533-541.
 - 18. Taylor-Papadimetriou, J., Lane, E.B. and Chang, S.E. (1983) In, Understanding Breast Cancer: Clinical and Laboratory Concepts. (Rich, M.A., Hager, J.C. and Purmanski, P. Eds.) Marcel Dekker, Inc. New York and Basel, pp. 215-246.
 - 19. Chang, S.E. and Taylor-Papadimitriou, J. (1983) Cell Diff. 12, 143-154.
- 20. Example 1 above.
- 35 21. Mort, A. and Lamport, D. (1977) Anal. Biochem. 82, 289-309.
 - 22. Wray, W., Boulikas, T., Wray, K.P. and Hancock, R. (1981) Anal. Biochem. 118, 197-203.
 - 23. Dubray, G. and Bezard, G. (1982) Anal, Biochem. 119, 325-329.
- 24. Shearer, M., Taylor-Papadimitriou, J., Griffin, D. and Balkwill, F. (1984) J. Immunol. 133, 3096-3101. 25. Durbin, H. and Bodmer, W.F. (1986) J. Immunol. Meth., In Press.
- 40 26. Lane, E.B. (1982) J. Cell Biol. 92, 665-673.
 - - 27. Gooi, H.C., Jones, N.J., Hounsell, E.F., Scudder, P., Hilkens, J., Hilgers, J. and Peizi, T. (1985) Biochem. Biophys. Res. Commun. 131, 543-550.
 - 28. Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J. and Rutter, W.J. (1979) Biochem. 18, 5194-5199.
- 29. Walter, P., Green, S., Greene, G., Krust, A., Bornort, J.-M., Heltsch, J.-M., Staub, A., Jensen, E., Scrace, G., 45 Waterfield, M. and Chambon, P. (1985) Proc. Natl. Acad. Sci. USA. 82, 7889-7893.
 - 30. Huynh, T.V., Young, R.A. and Davis, R.W. (1985) In, DNA Cloning: A Practical Approach, ed. Glover, D.M. (IRL, Oxford), Vol. 1, pp. 98-121.
 - 31. Young, R.A. and Davis, R.W. (1983) Proc. Natl. Acad. Sci. USA 80, 1194-1198.
- 32. Young, R.A. and Davis, R.W. (1983) Science 222, 778-782.
- 33. Vieira, J. and Messing, J. (1982) Gene 19, 259-268. 50
 - 34. Young, R.A. and Davis, R.W. (1985) In Genetic Engineering, eds. Setlow, J.K. and Hollaender, A. (Plenum, New York), Vol. 7.
 - 35. Laemmli, U.E. (1970) Nature (Lond) 227, 680-685.
 - 36. Towbin, H., Staehelin, Y. and Gordon, J. (1979) Proc, Natl. Acad, Sci. USA. 76, 4350-4354.
- 56 37. Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) Molecular Cloning: A Laboratory Manual (Coldspring Harbor Laboratory, Cold Spring Harbor, NY).
 - 38. Thomas, P.A (1980) Proc. Natl. Acad. Sci. USA. 77, 5201-5205.
 - 39. Woodhead, J.L., Pallon, R., Figueiredo, H., Langdale, J. and Malcolm, A.D.B. (1986) In Human Genetic Dis-

- eases, ed. Davies, K.E. (IRL, Oxford), p. 56.
- 40. Old, J.M. (1986) In Human Genetic Diseases, Ed. Davies, K.E., (IRL, Oxford), p.4.
- 41. Feinberg, A.P. and Vogelstein, B. (1984) Anal. Biochem. 137, 266-267.
- 42. Taylor-Papadimitriou, J., Purkis. P. and Fentiman, I.S. (1980) J. Cell. Physiol. 102, 317-321.
- Hackett, A.J., Smith, H.S., Springer, E.L., Owens, R.B., Nelsen-Rees, W.A., Riggs, J.L. and Gardner, M.B. (1977) J. Natl. Cancer Inst. 58, 1795-1800.
 - 44. Griffiths, A.B., Burchell, J., Taylor-Papadimitriou, J., Gendler, S.J., Lewis, A. and Tilly, R. (1987) Int. J. Cancer (submitted).
- Gottechalk, A., Bhargava, S. and Mury, V. In Gottechalk, A. (ed) Glycoproteins their composition, structure and function, pp. 810-829, Elsevier, New York.
 - 46. Hill, M.D.Jr., Reynolds, J.A. and Hill, R. (1977) J. Biol. Chem. 252, 3791-3798.
 - 47. Taylor-Papadimitriou, J., Millis, R., Burchell, J., Nash, R., Pang, L. and Gilbert, J. (1986) J. Expt. Path. 2, 247-260.
 - 48. Swallow, D., Griffiths, B., Bramwell, M., Wiseman, G. and Burchell, J. (1986) Disease Markers 3, In Press.
- Abe, M, and Kute, D. Effects of naturational agents on expression and accretion of two partially characterized high molecular weight milk-related glycoproteins in MCF-7 breast carcinoma cells. J. Cell, Physiol. 126:126-136, 1988.
- Arklie, J., Taylor-Papadimitriu, J., Bodner, W.F., Egan, M. and Millis, R. Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers, Int. J. Cancer 28:23-29, 1981.
- 51. Bolton, A.E. and Hunter, W.M. The labelling of proteins to high specific radioactivities by conjugation to a 1251 containing acytating agent. Biochem. J. 153:529-538, 1975.
 - Karlsson, S., Swallow, D., Griffiths, B., Comey, G. and Hoplinson, P. A genetic polymorphism of a human urinary mucin. Ann. Hum. Genet. 47:263-269, 1983.
- Kearney, J.F., Radbruch, A., Liesegang, B. and Rajowsky, K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of artibody-secreting hybrid cell lines. J. Immunol. 123: 1544-1550, 1979.
 - Melero, J. and Gonzalex-Rodrigues, J. Preparation of monoclonal antibodies against glycoproteins 111a of human platelets. Eur. J. Biochem. 141:421-427, 1984.
- Clamp, J.R., Allen, A., Gibbons, R.A. and Roberts, G. Chemical aspects of mucins, Br. Med. Bull. 34:25-41, 1978.

Claims

A nucleic acid fragment comprising at least 17 nucleotide bases the fragment being hybridisable with at least one of

a) the DNA sequence

5'

ACC GTG GGC TGG GGG GGC GGT GGA GCC CGG -

GGC CGG CCT GGT GTC CGG GGC CGA GGT GAC -

ACC GTG GGC TGG GGG GGC GGT GGA GCC CGG -

3'

GGC CGG CCT GGT GTC CGG GGC CGA GGT GAC

b) DNA ofsequence

51

5

15

25

40

45

50

GTC ACC TCG GCC CCG GAC ACC AGG CCG GCC -

CCG GGC TCC ACC GCC CCC CCA GCC CAC GGT -

GTC ACC TCG GCC CCG GAC ACC AGG CCG GCC -CCG GGC TCC ACC GCC CCC CCA GCC CAC GGT

- c) RNA having a sequence corresponding to the DNA sequence of a) and
- d) RNA having a sequence corresponding to the DNA sequence of b).
- 2. A nucleic acid fragment according to claim 1 comprising a portion of at least 30 nucleotide bases capable of hybridising with at least one of sequences (a) to (d).
- 3. A DNA fragment according to claim 1 or 2.
- 4. A double stranded DNA fragment comprising antiparallel paired portions having respectively sequences (a) and (b) as defined in claim 1.
- 5. A nucleic acid fragment according to any one of claims 1 to 4 bearing a detectable label or a therapeutically or diagnostically effective moiety.
 - 6. A nucleic acid fragment according to any one of claims 1 to 5 for use in a method of therapy or diagnosis practised on the human or animal body.
- 7. A diagnostic or therapeutic method practised on the human or animal body comprising administering a nucleic acid fragment according to any one of claims 1 to 6.
- 8. An antibody or fragment thereof against a human mucin core protein which antibody or fragment has reduced or substantially no reaction with fully expressed human mucin glycoprotein.
- 9. Human polymorphic epithelial mucin core protein
- 10. A polypeptide comprising 5 or more amino acid residues in a sequence corresponding to the sequence (I)

Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly

(I)

11. A polypeptide according to claim 10 having 20 or more amino acid residues in a sequence corresponding to the sequence (1)

Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly

(I)

- A polypeptide according to claim 10 or claim 11 wherein at least one amino acid residue bears a linkage sugar substituent.
 - 13. A polypeptide according to claim 12 wherein the linkage sugar bears an oligosaccharide moiety.
 - 14. A polypeptide according to claim 12 or claim 13 wherein amino acid bearing a substituent is a serine or threonine and the linkage sugar is N-acetyl galactosamine.
 - 15. A polypeptide according to any one of claims 12 to 14 linked to a carrier protein.

4

15

50

- 16. An antibody or fragment thereof against a polypeptide according to any one of claims 10 to 15 which antibody or fragment has reduced or substantially no reaction with fully processed human mucin glycoprotein.
 - 17. An antibody or fragment thereof according to claim 8 or claim 16 against a human polymorphic epithelial mucin core protein.
- 18. An antibody or fragment thereof according to claim 17 against human polymorphic epithelial mucin core protein as expressed by a human colon, lung, ovary or breast carcinoma.
 - 19. An antibody or fragment thereof according to any one of claims 8 and 18 to 18 which has no significant reaction with mucin glycoprotein expressed by pregnant or lactating human mammary epithelial tissue.
 - 20. A monoclonal antibody or fragment thereof according to any one of claims 8 and 16 to 19.
 - 21. A hybridoma cell capable of secreting a monoclonal antibody according to claim 20.
- 22. A hybridoma cell of the cell line designated HSM3 (ECACC 87010701).
 - 23. A monoclonal antibody secreted by HSM3 (ECACC 87010701).
- 24. An antibody of fragment thereof according to any one of claims 8, 16 to 20 and 23 bearing a detectable label or a therapeutically or diagnostically effective moiety.
 - 25. An antibody or fragment thereof according to any one of claims 8, 16 to 20, 23 and 24 for use in a method of therapy or diagnosis practised on the human or animal body.
- 45 26. Human polymorphic epithelial mucin core protein bearing a detectable label or a therapeutically or diagnostically effective moiety.
 - Human polymorphic epithelial mucin core protein according to claim 9 or claim 26 for use in a method of therapy or diagnosis practised on the human or animal body.
 - A polypeptide according to any one of claims 10 to 15 bearing a detectable label or a therapeutically or diagnostically effective moiety.
- A polypoptide according to any one of claims 10 to 15 and 28 for use in a method of therapy or diagnosis practised on the human or animal body.
 - 30. An assay method comprising contacting a sample suspected to contain abnormal human mucin glycoproteins with an antibody or fragment thereof according to any one of claims 8, 16 to 20, 23 and 24.

- 31. A diagnostic or therapeutic method practised on the human or animal body comprising administering an antibody or fragment thereof according to any one of claims 8, 16 to 20 and 23 to 25.
- 32. A diagnostic or therapeutic method practised on the human or animal body comprising administering human polymorphic epithelial mucin core protein according to any one of claims 9, 26 or 27.
- A diagnostic or therapeutic method practised on the human or animal body comprising administering a polypeptide
 according to any one of claims 10 to 15, 28 and 29.

10


15

20


25

35

55



⋖



14.3k D▶ 1 2

92.5kD▶ 69kD▶

46KD▶ 30KD▶

200KD▶





68KD> --

◆ ---<68KD

1 2

1 2

Fig.12.








Fig.6.




Fig.6.(Cont.d)




Fig.6.(Cont.d)





Fig.6.(Cont.d)



29

Fig.10.

200 K⊳

.

92.5 K ⊳

3 4 6 7 8 9 10

2028bp>

Fig.11.


603bp⊳

310 bp ⊳

ua

194 bp >

10 9 7 6 8 4 3





PARTIAL EUROPEAN SEARCH REPORT which under Rule 45 of the European Patent ConventionEP 00 12 7074 shall be considered, for the purposes of subsequent proceedings, as the European search report

		processings, as the european source	- Indian	,
		DERED TO BE RELEVANT		
Category	Citation of document with of relevant pa	Indication, where appropriate, scapes	Refevant to claim	CLASSIPICATION OF THE APPLICATION (INLCL?)
P,X	encoding different associated mucin g by human mammary PROCEEDINGS OF THE SCIENCES OF USA, NA SCIENCE, WASHINGTO	Nycoproteins expressed pithelium" NATIONAL ACADEMY OF TIONAL ACADEMY OF N.US, 1987 (1987-09), pages 9644	1-7, 10-16, 24-33	C1201/68 A61X31/70 C07K16/18 C07K14/47 C07K7/00 C12H5/20 A61X39/16 A61X39/395 G01N33/574
P,X	tumor-associated e coded by an expres locus PUM" NATURE, MACMILLAN J	pithelial mucins are sed hypervariable gene OURNALS LTD. LONDON,GB, 987 (1987-07-02), pages	1-33	TECHNICAL FIELDS SEARCHED INSCLU
		-/		C12Q C07K
INCOM	IPLETE SEARCH			
nol comply be carried Cisims so	with the EPC to much an extent the out, or can only be canned sel parts inched completely: arched incompletely.	of spokedistion, or one or more of its dearns, disease of a measurable more than the state of the sri or any, for these claims.	do unnot	
Alth meth 52(4	od of treatment of) EPC), the search	,27,29,31-33 are directed the human/animal body (A has been carried out and of the compound/composit	rticle based	
	Place of search	Date of complation of the selection	T	Ватем
	THE HAGUE	27 March 2001	Osb	orne, H
X : partx Y : partk doou A : tectro	TEGORY OF CITED DOCUMENTS substy relevant it taken alone substy relevant it continued with and relevant of the same category relegious backgrowned.	E : earlier patent doo, after the filling date ther D : document clad in L : document cted for	ment, but public the application other reasons	thed on, or
O non-	writen disclosure	& : member of the sar	no patent family	corresponding



European Paten

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 00 12 7074

	DOCUMENTS CONSIDERED TO BE RELEVANT		CLASSIFICATION OF THE APPLICATION (InLCLT)	
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to daim		
X	SENDERS S FT AL: "Molecular cloning and characterization of cDNAs coding for differentiation—and tumor—associated mucin glycoproteins expressed by human breast epithelium" JOURNAL OF CELL BIOLOGY, US, ROCKEFELLER UNIVERSITY FRESS, REY YORK, US, November 1986 (1986-11), page 27A XF00210846 [1986-11], page 27A SENSWEDS 1985 (1986-11), page 27A The November 1985 (1986-11), page 27A The November 1985 (1986-11), page 27A The November 1986 (1986-11), p	1-33		
	TAYLOR-PAPADIMITELDU J ET AL: "Patterns of expression of fearatins and mucins by mammary epithelial cells" BRITISH JOURNAL OF CANCER, GB. LONDON, vol. 54, no. 3. September 1986 (1986-09), pages 527-528, YEODZ109647 ISSN: 0007-0920 * the whole document *	1-33	TECHNICAL FELIOS SEARCHED (INCOLT)	
	SWALLOW D ET AL: "Detection of the urinary PUM polymorphism by the tumour binding monoclonal antibodies Cal. Ca2, Ca3, HMFG1, and HMFG2" DISEASE MAKERS, 68, MHLEY, CHICHESTER, vol. 4, no. 4, becamber 1988 (1986-12), 1588: 0278-0240 APRO2109048 * the whole document *	1-33		



European Pate

PARTIAL EUROPEAN SEARCH REPORT

EP 00 12 7074

	DOCUMENTS CONSIDERED TO BE RELEVANT	CLASSIFICATION OF THE APPLICATION (InLCLT)	
Calegory	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
x	MIAN N ET AL: "Characterization of core polypeptides of human bronchial mucins" BIOCHEMICAL SOCIETY TRANSACIONS, vol. 14, no. part 1, February 1986 (1986-02), pages 114-115, XP000990557 * the whole document *	1-7, 10-16, 24-33	
	BURCHELL J ET AL: "Development and characterization of breast cancer reactive motion of the street of the core control of a minimum lik mutin'. CAMCER RESEARCH, vol. 47, 18 (1987-10-15), pages \$476-82, XP000990648 * the whole document *	8,9	TECHNICAL FIELDS SEARCHED (HECLT)
	EP 0 369 816 A (UNIV MELBOURNE) 23 May 1990 (1990-05-23) * figure 1 *	1-33	
- 1	W9 90 05142 & (IMP CANCER RES TECH) 17 May 1990 (1990-06-17) 4 figures 2,3,5 *	1-33	
		-	

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 00 12 7074

dis	estent document ad in search rop	nt Hort	Publication date		Patent femily member(s)	Publication date
EP	0369816	A	23-05-1990	CA JP ZA	2003211 A 2273195 A 8908777 A	17-05-1990 07-11-1990 28-12-1990
WO.	9005142	A	17-05-1990	EP JP	0442926 A 4501719 T	28-08-1991 26-03-1992

For more details about this annex; see Official Journal of the European Patent Office, No. 12/82